NCT06764459 Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
| NCT ID | NCT06764459 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Myeloid Leukemia, Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-03-15 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2023-03-15 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their evolution during therapeutic treatment.
Eligibility Criteria
Inclusion Criteria: * FLT3 mutated Exclusion Criteria: * Respoder to therapy
Contact & Investigator
Emanuela Ottaviani, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06764459 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloid Leukemia, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06764459 currently recruiting?
Yes, NCT06764459 is actively recruiting participants. Contact the research team at emanuela.ottaviani@aosp.bo.it for enrollment information.
Where is the NCT06764459 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06764459 clinical trial?
NCT06764459 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Emanuela Ottaviani, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.